SearcharxivSearch

arXiv subjects

Andrew Z. Zhou

Publications and source records attributed to Andrew Z. Zhou.

2 recordsLinked to original sources

Navigating Gigapixel Pathology Images with Large Multimodal Models

Recent advances in large multimodal models have allowed for the development of interactive chat models that can converse and reason about pathology whole-slide images (WSIs). However, existing slide-level chat systems are often highly specialized, typically compressing WSIs into fixed slide-level embeddings or relying on multi-component pipelines, which can lose multi-scale detail and limit generalizability beyond the target task. We present GIANT (Gigapixel Image Agent for Navigating Tissue), a simple, training-free approach that lets general-purpose multimodal models navigate WSIs on their own, iteratively selecting multi-magnification crops and aggregating evidence over time. To evaluate generalizability in WSI question answering and to promote reproducibility, we introduce MultiPathQA, a benchmark suite spanning five clinical challenges and 934 questions over 868 unique WSIs. This includes a new set of 128 pathologist-authored multiple-choice questions designed to mirror real diagnostic search and multi-scale reasoning. Using GPT-5, GIANT outperforms models specialized for pathology question answering, achieving state-of-the-art performance on four out of five benchmarks.

cs.CV

Statin Recommendations among US Adults with the 2026 Dyslipidemia Guidelines

Importance: The 2026 multisociety dyslipidemia guideline recommended the PREVENT equations in place of the PCE equations, introduced 30-year risk assessment as a new treatment pathway, and lowered risk-based treatment thresholds. The net population impact of these concurrent changes on statin recommendations is unknown. Objective: To estimate changes in statin recommendations under 2026 PREVENT-based dyslipidemia guidelines compared with 2018 PCE-based guidelines. Design and Participants: Cross-sectional analysis of pooled data from NHANES, spanning 2011-2023 and comprising 24,199 participants aged 30-79 years. Main Outcomes and Measures: Number and proportion of US adults receiving or recommended for statin therapy. Results: At the class 1 threshold, the number of US adults receiving or recommended for statin therapy decreased by an estimated 3.0 million (95% CI, 2.3 million to 3.6 million), with larger reductions among Black adults (-4.2 percentage points [pp]), men (-4.0pp), and adults aged 50-69 years (-5.6pp). At the class 2 threshold--which additionally recommends statins for adults aged 30-59 years based on 30-year risk--the number of adults recommended increased by an estimated 20.8 million (95% CI, 19.6 million to 22.0 million), or +11.6pp. The increase was largest among adults aged 50-59 years (+19.7pp) and 40-49 years (+14.8pp). Conclusions: The net population impact of the 2026 dyslipidemia guidelines depends critically on which recommendation class is applied. At the class 1 threshold, statin recommendations decreased modestly; at the class 2 threshold, inclusion of 30-year risk assessment substantially expanded recommendations, particularly among younger adults. These divergent effects underscore the importance of the 30-year risk criterion as a major driver of new eligibility and the need for outcomes and equity monitoring during guideline implementation.

q-bio.OT